Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic DiseaseAUSTIN, Texas, Jan. 26, 2022 (GLOBE NEWSWIRE) XBiotech Inc.
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0176 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
21st Austria weekly - CA Immo Marinomed Palfinger 22/11/2021 [pic1]Marinomed Biotech: an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms today reported the financial results for first nine months 2021. Revenue increased by 12.9 % to Euro 5.7 mn in three quarters of 2021 9M 2020: 5.1 mn. In addition governmental funding R&D activities and other income generated another 1.4 mn resulting a 21.2 increase total 7.1 5.9 Total expenses both Carragelose Marinosolv amounted 6.1 3.9 million mainly due additional clinical studies SARS-CoV-2. Therefore loss was at 6.3 fully line expectations 4.8 Marinomed performance: -5.60%
21st Austria weekly - CA Immo Marinomed Palfinger 22/11/2021 [pic1]Marinomed Biotech: an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms today reported the financial results for first nine months 2021. Revenue increased by 12.9 % to Euro 5.7 mn in three quarters of 2021 9M 2020: 5.1 mn. In addition governmental funding R&D activities and other income generated another 1.4 mn resulting a 21.2 increase total 7.1 5.9 Total expenses both Carragelose Marinosolv amounted 6.1 3.9 million mainly due additional clinical studies SARS-CoV-2. Therefore loss was at 6.3 fully line expectations 4.8 Marinomed performance: -5.60%
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After StrokeAUSTIN, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) XBiotech (NASDAQ: XBIT) announced